Bone mineral density in a cohort of adolescent women using depot medroxyprogesterone acetate for one to two years

Journal of Adolescent Health

Volumn 32, Issue 4, 2003, Pages 257-259

  Busen, Nancy H ^c   Britt, Robin B ^a   Rianon, Nahid ^b  

^a TEXAS WOMAN'S UNIVERSITY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON   (United States)

Author keywords

Adolescents; Bone mineral density; Contraception; Depot medroxyprogesterone acetate

Indexed keywords

ESTRADIOL; MEDROXYPROGESTERONE ACETATE;

ADOLESCENT; ADULT; ARTICLE; BONE DENSITY; COHORT ANALYSIS; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTRADIOL BLOOD LEVEL; FEMALE; FEMUR NECK; HUMAN; LONG TERM CARE; LUMBAR SPINE; NORMAL HUMAN; PRIORITY JOURNAL; QUESTIONNAIRE;

EID: 12244257571     PISSN: 1054139X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1054-139X(02)00567-0     Document Type: Article

References (10)

1. Speroff L., Glass R., Kase N. Clinical Gynecologic Endocrinology and Infertility. 1994;Williams & Wilkins, Baltimore, MD.
2. Cundy T., Evans M., Roberts H., et al. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ. 303:1991;13-16.
3. Cromer B., Blair J., Mahan J., et al. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr. 129:1996;671-676.
4. Cundy T., Cornish J., Roberts H., et al. Spinal bone density in women using depot medroxyprogesterone contraception. Obstet Gynecol. 92:1998;569-573.
5. Scholes D., Lacroix A., Ott S., et al. Bone mineral density in women using depot medroxyprogesterone acetate for contraception. Obstet Gynecol. 93:1999;233-238.
6. Petitti D., Piaggio G., Mehta S., et al. Steroid hormone A cross-sectional study in an international population . Obstet Gynecol. 95:2000;736-744.
7. Cundy T., Cornish J., Evans M., et al. Recovery of bone density in women who stop using medroxyprogesterone acetate. BMJ. 308:1994;247-248.
8. Burkman T. Oral contraceptives Current status . Clin Obstet Gynecol. 44:2000;62-72.
9. Mishell D. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med. 41:1996;381-390.
10. LeBlanc A., Driscoll T., Shackelford L., et al. Alendronate as an effective countermeasure to disuse induced bone loss. J Musculoskel Neuron Interact. 2:2002;335-343.